Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Relapse after high-dose chemotherapy supported by peripheral blood stem cell transplantation (HDC-PBSCT) is the main cause of therapeutic failure in patients with lymphoma and breast cancer. Adoptive immunotherapy with activated natural killer (A-NK) cells and interleukin 2 might eliminate surviving residual tumor without adding to toxicity. Eleven patients with relapsed lymphoma and one with metastatic breast cancer were entered on a pilot clinical trial of HDC-PBSCT followed on day 2 after transplant by infusion of cultured autologous A-NK cells. Simultaneously, recombinant human interleukin 2 (rhIL-2) was initiated as a 4-day continuous i.v. infusion at 2 x 10(6) IU/m2/day, referred to as high-dose rhIL-2. Therapy with high-dose rhIL-2 was followed by a 90-day continuous i. v. infusion at 3 x 10(5) IU/m2/day, referred to as low-dose rhIL-2. All patients engrafted and nine completed treatment. Posttransplant days to a neutrophil count of 500/microliter and to a platelet count of 50,000/microliter were similar to comparable patients treated with HDC-PBSCT alone. Generation of A-NK cells for therapy was feasible in all patients except the three patients with Hodgkin's disease, whose cells did not proliferate in culture. Overall toxicity associated with early posttransplant transfer of A-NK cells and interleukin 2 did not differ from that observed with peripheral blood stem cell transplantation alone in comparable patients. There was early amplification of natural killer cell activity in the peripheral blood of four patients that appeared to result from the transfused A-NK cells. Adoptive transfer of A-NK cells and rhIL-2 during the pancytopenic phase after HDC-PBSCT was feasible and well tolerated, did not adversely affect engraftment, and resulted in amplified natural killer activity in the peripheral blood during the immediate posttransplantation period.
Lister
J
J
Division of Hematology/Bone Marrow Transplantation, Department of Medicine, Pittsburgh Cancer Institute, Pennsylvania 15213-2582,
Rybka
W B
WB
Donnenberg
A D
AD
deMagalhaes-Silverman
M
M
Pincus
S M
SM
Bloom
E J
EJ
Elder
E M
EM
Ball
E D
ED
Whiteside
T L
TL
D019264:Adoptive Transfer; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy; D002066:Busulfan / Q000627:therapeutic use; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology*; D017710:Lymphocyte Transfusion; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D010865:Pilot Projects; D010976:Platelet Count; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; D003520:Cyclophosphamide; D002066:Busulfan; D007069:Ifosfamide